Atara Bio's tab-cell shows durable effect in mid-stage studies in EBV-associated post-transplant lymphomas; shares up 1% [Seeking Alpha]
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: Seeking Alpha
Atara Bio's tab-cell shows durable effect in mid-stage studies in EBV-associated post-transplant lymphomas; shares up 1%Long-term results from two Phase 2 clinical trials evaluating Atara Biotherapeutics' (ATRA+0.9%) off-the-shelf T-cell immunotherapy tabelecleucel (tab-cel) in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (EBV+PTLD) showed sustained benefits. The data were presented at the EHA Congress in Stockholm.The studies assessed tab-cell in EBV+PTLD patients following hematopoietic cell transplant (HCT) or solid organ transplant (SOT) who failed first-line treatment with Roche's Rituxan (rituximab).One- and three-year overall survival (OS) rates were 68% and 55%, respectively, in EBV+PTLD patients following HCT. Median OS was not reached after 23.3 months of follow-up, significantly greater than the expected 16 - 56 days for this patient population.In EB+PTLD patients following SOT, one- and three-year OS rates were 64% and 43%,
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target lowered by analysts at Stifel Nicolaus from $4.80 to $2.30. They now have a "hold" rating on the stock.MarketBeat
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressBusiness Wire
ATRA
Earnings
- 3/28/24 - Beat
ATRA
Analyst Actions
- 4/1/24 - Stifel
ATRA
Sec Filings
- 4/12/24 - Form PRE
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ATRA's page on the SEC website